Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 2/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 2/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 4/20 | 0.49 |
| ▸ | MMP9 | P14780 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933401 | 1.00 | ACE (0.56) | ACENPSR1FPR2ECE1MME | |
| SCHEMBL71782 | 1.00 | ACE (0.56) | ACENPSR1FPR2ECE1MME | |
| SCHEMBL8823272 | 0.86 | ACE (0.58) | ACEMMECPA1NAALAD2L3MBTL1 | |
| SCHEMBL21326281 | 0.86 | EPHX1 (0.49) | ACENPSR1FPR2ECE1CPA1 | |
| SCHEMBL21326284 | 0.86 | EPHX1 (0.49) | ACENPSR1FPR2ECE1CPA1 | |
| SCHEMBL8823270 | 0.86 | ACE (0.58) | ACEMMECPA1NAALAD2L3MBTL1 | |
| SCHEMBL29022675 | 0.85 | FPR2 (0.50) | ACENPSR1FPR2MMEMMP2 | |
| SCHEMBL6402000 | 0.85 | SLC7A5 (0.56) | ACEALDH1A1 | |
| SCHEMBL6401999 | 0.85 | SLC7A5 (0.56) | ACEALDH1A1 | |
| SCHEMBL5772094 | 0.83 | ATM (0.57) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334759-B1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | FARMAGENS HEALTH CARE SRL (IT) | 2019-09-04 | — | — | EP | claimed |
| EP-3334759-A1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | Farmagens Health Care Srl (IT) | 2018-06-20 | — | — | EP | claimed |
| WO-2017025846-A1 | LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT | FARMAGENS HEALTH CARE SRL (IT) | 2017-02-16 | — | — | WO | claimed |
| US-20030143664-A1 | Products of manufacture and processes for peptide synthesis | DIVERSA CORPORATION (US) | 2003-07-31 | — | — | US | claimed |
| WO-2003048189-A2 | PRODUCTS OF MANUFACTURE AND PROCESSES FOR PEPTIDE SYNTHESIS | DIVERSA CORPORATION (US) | 2003-06-12 | — | — | WO | claimed |
| US-12037386-B2 | Antibodies to PfGARP kill Plasmodium falciparum malaria parasites and protect against infection and severe disease | RHODE ISLAND HOSPITAL (US) | 2024-07-16 | — | — | US | disclosed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| EP-4389757-A2 | METHODS FOR PURIFYING ANTIBODIES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024129720-A2 | T CELL RECEPTOR CONSTRUCTS AND USES THEREOF | BIONTECH US INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-118076632-A | Conditionally active proteins for neurodegenerative diseases | 生物蛋白有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3510042-B1 | METHODS FOR PURIFYING ANTIBODIES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| US-5508384-A | NEUROLEPTIC AGENTS WITH REDUCED SIDE EFFECTS | NEW YORK UNIVERSITY (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1995022561-A2 | PEPTIDES RECOGNIZED BY MELANOMA-SPECIFIC CYTOTOXIC LYMPHOCYTES, AND USES THEREFOR | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1995-08-24 | — | — | WO | disclosed |
| WO-1995020397-A1 | PHOSPHACAN, NUCLEIC ACIDS ENCODING THEREOF AND ANTIBODIES THERETO | NEW YORK UNIVERSITY (US) | 1995-08-03 | — | — | WO | disclosed |
| WO-1995013828-A1 | BENEFICIAL WOUND HEALING APPLICATIONS OF CALRETICULIN AND OTHER HYALURONAN-ASSOCIATED PROTEINS | NEW YORK UNIVERSITY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995013291-A1 | NEURON-GLIA CELL ADHESION MOLECULE, NG-CAM, IN TREATMENT OF NERVE DAMAGE | NEW YORK UNIVERSITY (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1994005695-A9 | POLYPEPTIDES OF G-COUPLED RECEPTOR PROTEINS, AND COMPOSITIONS AND METHODS THEREOF | — | 1994-05-11 | — | — | WO | disclosed |
| WO-1994003601-A9 | CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN | — | 1994-03-31 | — | — | WO | disclosed |
| WO-1994003601-A2 | CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN | NEW YORK UNIVERSITY (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | ACE 319/4885NPSR1 4325/4885FPR2 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.